EOLS - Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conference in April:

Event: The 23 ^rd Annual Needham Virtual Healthcare Conference
Date: Tuesday, April 9 ^th , 2024
Time: 9:30 – 10:10 AM ET

The fireside chat can be accessed on the Investor Relations page of the Evolus website here . A replay of the webcast will be available for 90 days following the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau ^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme ^® , a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com , and follow us on LinkedIn , X , Instagram or Facebook .

Jeuveau ^® and Nuceiva ^® are registered trademarks of Evolus, Inc.
Evolysse ^™ is a trademark of Evolus, Inc.
Hi-Pure ^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240326735225/en/

Investors:
Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications
Phone: (248) 202-9267
Email: ir@evolus.com

Media :
Email: media@evolus.com